compounded semaglutide shortage & Tirzepatide 2025: Safe Use Guide FDA sets tirzepatide compounding deadlines

FDA Approval Status of Retatrutide Retatrutide is classified as a research compound and is not approved by the FDA for human consumption or medical use

Obese Zucker rats treated with AOD-9604 at 500 mcg/kg/day for 19 days showed a statistically significant reduction in body fat compared to vehicle-treated controls

The blood sugar benefits extend far beyond diabetes treatment

Overview Retatrutide is a synthetic, long-acting triple agonist that targets three distinct hormonal receptors: the glucagon-like pep-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor (GCGR)